WO2006087723A2 - Dispositif et procede de luminotherapie multi-niveau - Google Patents

Dispositif et procede de luminotherapie multi-niveau Download PDF

Info

Publication number
WO2006087723A2
WO2006087723A2 PCT/IL2006/000212 IL2006000212W WO2006087723A2 WO 2006087723 A2 WO2006087723 A2 WO 2006087723A2 IL 2006000212 W IL2006000212 W IL 2006000212W WO 2006087723 A2 WO2006087723 A2 WO 2006087723A2
Authority
WO
WIPO (PCT)
Prior art keywords
light
time
lux
intensity
window
Prior art date
Application number
PCT/IL2006/000212
Other languages
English (en)
Other versions
WO2006087723A3 (fr
Inventor
Lucian Moscovici
Original Assignee
Mata Temed Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mata Temed Ltd. filed Critical Mata Temed Ltd.
Priority to US11/884,299 priority Critical patent/US8852254B2/en
Priority to EP06711194A priority patent/EP1850912A4/fr
Publication of WO2006087723A2 publication Critical patent/WO2006087723A2/fr
Priority to IL185243A priority patent/IL185243A/en
Publication of WO2006087723A3 publication Critical patent/WO2006087723A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A61N5/0618—Psychological treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/065—Light sources therefor
    • A61N2005/0651—Diodes
    • A61N2005/0652—Arrays of diodes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
    • A61N2005/0662—Visible light

Definitions

  • the present invention relates to light treatment useful for treating psychiatric, mood and/or circadian rhythm disorders, and to apparatus for providing the same.
  • psychiatric disorders are considered to be the second between the seven leading global health problems in the world today (1).
  • Depression is a common disorder, widely distributed in the population with 16.2% prevalence and is associated with substantial symptom severity and role impairment (2).
  • Seasonal Affective Disorder (SAD) is also common in certain areas of the world, with prevalence rates increasing with latitude: about 10% in Alaska and Canada (3,4), between 5.6-10.7% in UK (5), 8.9% in Central Europe (6) and only 3.7-6.6% in Turkey (7).
  • SAD Seasonal Affective Disorder
  • Another major medical problem of the western civilization is Binge Eating Disorder. 6% of women population of the world will suffer from this eating disorder sometime during their life.
  • Sleep disorders as insomnia and sleep schedule disorders affect as much as 20% of the adult population and is increasing with age (9).
  • BLT Broad Spectrum Bright Light Therapy
  • BLT implies the use of a Light Box (34) that uses fluorescent or neon light sources capable of producing wide/broad- spectrum white light between 2500-100001ux.
  • the Light Boxes usually filter the UV light (below 400 nm).
  • the therapy consists of early morning exposure for about 30-60 minutes every day.
  • An alternative to Light Box is the Light Visor, a small light device mounted on the head that produces 20001ux bright light directly to the eyes (35).
  • US 6,875,225 discloses a light therapy device capable of generating 2,500 lux to 7,500 lux at 12 inches.
  • the biologic mechanism of light therapy involves the activation via optic pathways of the suprachiasmatic nucleus of the hypothalamus, inhibition of the melatonin production by the pineal gland and increase of the central serotonin level in the limbic system. (36).
  • Another well-studied light therapy is Dawn/Dusk Simulation (DS)(37, 38). This therapy is acting on the melatonin cycle and is based on gradual increases of light while the patient is asleep, until a maximum brightness of 400 lux is achieved, thus mimicking the natural sunrise or sunset.
  • DS is as effective as BLT, but have a better compliance because it works while the patient is steel asleep.
  • the existing dawn simulators are using bulbs capable of gradually (30-60 minutes) increasing the light to a maximum 4001ux only.
  • Another well recognized non-pharmacologic therapy for depression is Sleep Deprivation (Wake Therapy). About 40-60% of the depressive symptoms improve after one night of sleep deprivation or after partial sleep deprivation of the second part of the night (39).
  • Combined sleep deprivation and light therapy have been described in the literature (40,41,42), and considered to be superior to each therapy alone.
  • Color Light Therapy is actually used as a traditional oriental medicine (acupuncture, ayurveda) (43). All existing light devices have many limitations: The compliance of the patients using
  • Light Boxes may be problematic because the treatment must be followed every day at early morning hours, while the patient is fully awake and the distance and the position of the device must be controlled. All these parameters are important for the efficacy of the treatment, but they depend on the cooperation with the patient and his understanding of the method. Light Visors are considered less effective than Light Boxes, the light brightness is of only 2000 lux but very close to the eyes, thus provoking unpleasant eye irritation. The dawn simulators are based on a different light therapy method (simulating the natural dawn) and have a better compliance because it works while the patient is asleep, but the spectrum and brightness are limited (e.g. maximum 400 lux) , which are not enough for a true BLT.
  • Wake therapy is not a device but a method and is not actually used in the clinical practice because when used alone, its antidepressant effect is transient.
  • Some devices using specific colors of the spectrum green, blue
  • WO 2005/004948 discloses a method for modifying or resetting the circadian cycle using short wavelength light.
  • Novel, effective, evidence based non-drug treatments for depression, anxiety, eating and sleep disorder are important challenges of the third millennium for a number of reasons:
  • the first time apparatus comprising: (a) a light source; and (b) a controller said controller operative to (i) effect, using said light source, a first stage of light emission including a first time window of 20 minutes during which, for a majority of the time of said first time window, the light intensity at a predetermined distance is equal to at least a low-intensity minimum value of at least about 50 lux and is equal to at most a low-intensity maximum value of at most about 2000 lux (ii) to effect,, subsequent to said first time window, using said light source, a second stage of light emission including a second time window of at least 60 minutes wherein for every 45 minute sub-window within said second time window, the light intensity at said predetermined distance, for a majority of the time of said sub- window, is equal to at least a second minimum value of at least about 100 lux; and (iii) to effect, subsequent to said second time
  • the term "sub-window within the second time window” refers to a time window that is contained within the "second time window.”
  • the low-intensity minimum value is 100 lux, or 200 lux, or 300 lux, or 400 lux.
  • the low-intensity maximum value is 2000 lux, or 1500 lux, or 1200 lux, 1000 lux, or 800 lux.
  • the apparatus is configured such that an intensity emitted from said light source at said predetermined distance during a majority of the time of said second time window and during a majority of the time of said third time windows is at most 20,000 lux.
  • the apparatus is configured such that an intensity emitted from said light source at said predetermined distance during a majority of the time of said second time window and during a majority of the time of said third time windows is at most 15,000 lux.
  • the apparatus is configured such that an intensity emitted from said light source at said predetermined distance during a majority of the time of said second time window and during a majority of the time of said third time windows is at most 12,000 lux.
  • said controller is operative to effect said first, second and third stages such that an elapsed time between a beginning of said first time window and a beginning of said third time window is at most a maximum elapsed time value of 8 hours.
  • said controller is operative to effect said first, second and third stages such that an elapsed time between a beginning of said first time window and a beginning of said third time window is at most a maximum elapsed time value of 6 hours.
  • said light source includes a plurality of LEDs.
  • at least some said LEDS are white LEDS and at least some said LEDs are colored LEDS.
  • said low-intensity minimum value is at least 600 lux.
  • said controller is configured such that said first stage of light treatment includes a simulated dawn process wherein the intensity of light gradually at said predetermined distance increases from substantially zero lux (for example, less than 50 lux) to between 500 lux and 1200 lux over a period of between 30 minutes and 75 minutes.
  • said controller is configured such that said first time window is preceded by an lower intensity time window of 20 minutes during which, for a majority of the time, the light intensity at said predetermined distance is equal to at least a lower-intensity minimum value of 100 lux and is equal to at most a lower-intensity maximum value of 400 lux.
  • said controller is configured such that said second window includes a fourth time window of at least 45 minutes wherein for every 10 minute period within said fourth time window, the light intensity at said predetermined distance is equal to at most a value of 1500 lux.
  • said controller is configured such that for every said 10 minute period within said fourth time window, the light intensity at said predetermined distance is equal to at least a value of 2500 lux.
  • said controller is configured such that for every non- overlapping 15 minute period within said second time window, a value of an average light intensity at said predetermined distance during a latter said non-overlapping time period exceeds or is substantially equal to a value of an average light intensity at said predetermined distance during an earlier said non-overlapping time period.
  • said controller is configured such that a duration of said second time window is at least 150 minutes.
  • said controller is configured such that a duration of said second time window is at least 180 minutes.
  • said high-intensity minimum value is 5000 lux, or 7500 lux, 9500 lux.
  • said controller is configured such that said third stage further includes a fourth time window of 60 minutes distinct from said third time window, during which, for a majority of the time, the light intensity at said predetermined distance is equal to at least said high-intensity minimum value.
  • said controller is configured such that at least one of light emitted from said light source of said majority of the time of said first window and light emitted from said light source of a majority of the time of said second window comprises both white light and colored light having a wavelength of less than 550 nanometers.
  • said controller is configured such that said light emitted from said light source of said majority of the time of said first window comprises at least 5% colored light and at most 30% colored light.
  • said controller is configured such that said light emitted from said light source of said majority of the time of said second window comprises at least 20% colored light and at most 60% colored light.
  • said colored light having a wavelength of less than 550 nanometers is green light having a wavelength between 520 nm and 535 nanometers.
  • said controller is configured such that at least one of light emitted from said light source of said majority of the time of said first window and light emitted from said light source of a majority of the time of said second window comprises at least 40% white light
  • said controller is configured to effect said first, second and third stages for a plurality of days at a time that is substantially the same time of day.
  • said controller is configured to effect said first, second and third stages for at least one day, and on days following said at least one day, said controller is configured to effect at least one day to a fourth stage of light treatment, wherein: (i) said fourth stage of light treatment includes at least 30 minutes of high intensity light treatment administered within a 60 minute period and administered at a time of day substantially identical to a time of day of said third time window, and (ii) a duration of said fourth stage is equal to at most 30% less than an elapsed time between a beginning of said first time window and an end of said second time window.
  • the apparatus is configured such that light emitted from said light source said during majority of the time of said first time window of said first stage comprises at least 50% white light (i.e. broad spectrum white light). According to some embodiments, the apparatus is configured such that light emitted from said light source said during every said majority of the time of said second time window of said second stage comprises at least 50% white light (i.e. broad spectrum white light).
  • the apparatus is configured such that light emitted from said light source said during majority of the time of said third time window of said third stage comprises at least 50% white light (i.e. broad spectrum white light).
  • said second minimum value is 300 lux, or 400 lux, or 500 lux, or 750 lux, or 1000 lux, or 1250 lux, or 1500 lux.
  • said controller is configured such for every 30 minute sub- window within said second time window the light intensity at said predetermined distance, for a majority of the time, is equal to at least said second minimum value
  • said controller is configured such for every 20 minute sub-window within said second time window the light intensity at said predetermined distance, for a majority of the time, is equal to at least said second minimum value. According to some embodiments, said controller is configured such for every 10 minute sub-window within said second time window the light intensity at said predetermined distance, for a majority of the time, is equal to at least said second minimum value.
  • said controller is configured such that a duration of said second time window is at least 120 minutes. According to some embodiments, said controller is configured such that a duration of said second time window is at least 90 minutes.
  • said controller is configured such that a duration of said third time window is 40 minutes.
  • said controller is configured such that a duration of said third time window is 60 minutes.
  • said controller is configured such that a duration of said third time window is 75 minutes.
  • the apparatus is adapted to shut off (i.e. shut off at least the light source, and optionally the electronics of the controller) no later than 120 minutes after the end of said third window. According to some embodiments, the apparatus is adapted to shut off no later than 60 minutes after the end of said third window.
  • the apparatus is adapted to shut off no later than 30 minutes after the end of said third window. According to some embodiments, the apparatus is adapted to shut off no later than immediately after the end of said third window.
  • controller of the device may be adapted to lower the intensity of the light after the bright light therapy provided by the device has concluded.
  • controller is further operative to (iv) effect, no later than immediately after 60 minutes after the end of said third time window (or alternatively, no later than immediately after the end of said third time window), a decreased light stage whose duration is at least 20 minutes, wherein an intensity of light emitted from said light source at said predetermined distance is at most a fraction whose value is at most 0.99 of said high-intensity minimum value
  • a duraction of said decreased light stage is at least 60 minutes, or alternatively, at least 120 minutes.
  • said value of said fraction is about 0.9, or alternatively about 0.7, about 0.5, about 0.3, about 0.2, about 0.1, about 0.1, or about 0.01.
  • the apparatus and/or controller is configured such that for a majority of the time of said second time window, the light intensity at said predetermined distance is equal to at most a second maximum value of at most about 10,000 lux.
  • the value of the second maximum value may be 10,00 lux, 7,500 lux, 5,000 lux, 2,500 lux, 2,000 lux and 1,500 lux. It is noted that the presently disclosed apparatus is useful for treating at least one of a psychiatric disorder, a mood disorder and a circadian rhythm disorder.
  • FIG. 1A-1B illustrate a graph of light intensity as a function of time according to exemplary embodiments of the present invention.
  • FIG. 2 provides a block diagram of a light treatment apparatus according to. exemplary embodiments of the present invention.
  • FIG. 3 provides an illustration of exemplary light source elements.
  • the present inventor is now disclosing an apparatus and a method for providing a novel light treatment for a number of psychiatric, mood and circadian rhythm disorders, including, but not limited to non-seasonal depression, premenstrual syndrome, binge eating, seasonal depression and circadian rhythm disorders.
  • the presently disclosed treatment provides sleep deprivation by light (i.e. extended sleep deprivation of at least 2 Vi hours, more preferably at least 3 hours, most preferably at least 3 1 A hours) in combination with bright light therapy.
  • extended sleep deprivation of at least 2 Vi hours, more preferably at least 3 hours, most preferably at least 3 1 A hours
  • the patient is awakened with a simulated dawn process, and then subjected, for an extended period of time, to light that is bright enough to keep the patient awake and includes a phase of "bright light” therapy.
  • the patient is subjected to a mixture of white light (i.e. broad spectrum white light) and medium wavelength light.
  • the presently disclosed light treatment may provide up to four synergistic therapies: sleep deprivation therapy (for example, extended sleep deprivation therapy), bright light therapy, dawn simulation therapy, and medium wavelength light therapy.
  • sleep deprivation therapy for example, extended sleep deprivation therapy
  • bright light therapy for example, dawn simulation therapy
  • medium wavelength light therapy for example, medium wavelength light therapy.
  • a novel light treatment comprising several stages is administered to a patient.
  • This multi-stage light treatment protocol will be explained with reference to FIGS. IA- IB, which provides exemplary graphs of the light intensity (for example, at a distance of about 18 inches from the light source, for example, near the patient's eyes) as a function of time. It is noted that the graphs of FIGS. 1A-1B are not to scale.
  • the patient is subjected to a light treatment which includes a first time window 110 of 20-40 minutes (for example, 20 minutes) during which, for a majority of the time, the light intensity is equal to at least a low-intensity minimum value of 50 lux and is equal to at most a low-intensity maximum value of 2000 lux.
  • the low- intensity minimum value is 300 lux and the low-intensity maximum value is 1200 lux, though this should not be construed as a limitation.
  • the purpose of the first stage of light treatment is to wake the patient gently, so as not to agitate the patient, but firmly, in order that the patient remain awake and not return to sleep.
  • a light intensity of less than 300 lux would probably not suffice to wake many patients, though this exact number could, of course, vary between patients.
  • this first time window is typically often provided in the context of a "dawn stage" 102 to awaken a slumbering patient.
  • the light intensity exceeds 1200 lux, many patients could get agitated (though this too could vary among patients), which may be an undesirable outcome.
  • this simulated dawn process is characterized by a gradual increase in light intensity, from an extremely low intensity of light (i.e. less than 200 lux, or preferably less than 100 lux) to an intensity whose value is equal to at least the low-intensity minimum value and at most the low-intensity maximum value.
  • a "gradual increase" refers to a gradual increase as experienced by the user and includes cases where there are transient variations that do not significantly impact on the overall effect experienced by the patient.
  • the simulated dawn process 102 has of duration between 20 and 90 minutes including the first window 110.
  • the simulated dawn process has a duration of between 30 minutes and 75 minutes.
  • the exact intensity for any given individual during the time of the first window 110 may vary as a function of the patient subjected to the light treatment. For example, for certain individuals, who are "heavier sleepers," the low-intensity minimum value may be set to be at least 600 lux, or at least 800 lux.
  • the low-intensity maximum value may be set to be less than 1200 lux, for example, at most 1000 lux, or lower.
  • the first window 110 is typically provided within the context of a dawn simulation characterized by a gradual increase in the light intensity.
  • the first time window 110 is proceeded by another "lower intensity time window 118" where the light intensity is even lower, for example, between a lower- intensity minimum value of 100 lux and a lower-intensity maximum value of 400 lux.
  • the light intensity typically gradually increases gradually.
  • the device providing the light treatment is configured such that the first window 110 is begins after only 1-4 hours of sleep, so as to wake the patient in the middle of a night's sleep and to deprive the patient of sleep.
  • the patient is subjected to a second stage 104 of light treatment, where the intensity of light is maintained at a level so as to deprive the patient of sleep.
  • This second stage 104 of light treatment includes a second time window 112 of at least 90 minutes wherein for every 10 minute period, the light intensity, for a majority of time, is equal to at least a second minimum value of 100 lux.
  • This intensity should be sufficient to keep the patient awake.
  • a second minimum value of 300 lux, or 500 lux, or of 1000 lux, or of 1500 lux is desired to keep the patient awake.
  • the second minimum value is at least 1000 lux, or alternatively at least 1500 lux, or alternatively at least 2000 lux.
  • periods of time where the intensity of light decreases are not outside of the scope of the invention, it is noted that typically the light intensity is constant or increasing as a function of time, throughout the majority of time of the second stage 104, and in particular during part, the majority, or substantially the entire the second time window 112, in order to avoid an impression of a setting sun which may hinder the sleep deprivation process.
  • the exact profile of light intensity as a function of time required to maintain the wakeful state of any given patient will also vary between patients.
  • the second time window is at least 150 minutes, and in some embodiments, the second time window is at least 180 minutes.
  • the second stage 104 of light treatment may provide a transition between the period of low intensity light treatment (i.e. that of the first window 110), and the period of high intensity light treatment (i.e. that of the third window 114).
  • the second window 112 includes a period of time when the intensity of light gradually increases.
  • the rate of increase need not be substantially constant, as in the example of FIG. IA.
  • the rate of increase towards the end of the period of time of the second window 112 is greater than the rate of increase in the beginning of the second window 112.
  • This "crescendo effect" may allow for a smooth increase in light intensity without overexposing the patient to too long a period of time of intense light.
  • This intensity profile may be useful for embodiments where the light intensity during the third window 114 is on the order of magnitude of 6,000 - 10,000 lux.
  • a value of the average light intensity during a latter non-overlapping time period exceeds or is equal to a value of the average light intensity during an earlier non-overlapping time period.
  • the present inventor is disclosing a synergy between extended sleep deprivation and bright light therapy.
  • the light therapy may be augmented with music in order to help the patient remain awake during the period of treatment.
  • Stage 3 - Bright Light Therapy 106 The benefits of bright light therapy for certain mood and psychiatric disorders are well known. The present inventor is disclosing that the subjecting the patient to a protocol which provides extended sleep deprivation as well as bright light therapy provides a synergistic effect which is useful for treating these disorders.
  • the third stage includes a third time window of 30-60 minutes (for example 60 minutes) during which light intensity is equal to at least a high-intensity minimum value.
  • the high intensity minimum value of the third window 114 is 9,500 lux.
  • the high intensity minimum value of the third window 114 is 5,000 lux.
  • the high intensity minimum value of the third window 114 is 2,500 lux.
  • the light intensity during this third window 114 remains substantially constant, though this is certainly not a limitation, and embodiments where the light intensity fluctuates while remaining above the "high intensity minimum value" during the majority of the 60 minute period of the third window 114 are contemplated.
  • the light intensity is kept below certain values (for example 20,000 lux, or below 15,000 lux, or below 10,000 lux) during periods of time in the second and third time windows.
  • the amount of time of bright light therapy may be extended beyond what is illustrated in FIGS. 1A-1B.
  • the three-stage light treatment protocol described herein is provided as a single treatment, and it is preferred that the patient remains in proximity of the light device throughout the period of time of treatment.
  • the total length of time of "single treatment" is typically between about 3 hours and usually no more than 6 hours.
  • the elapsed time between the beginning of the first time window 110 and the beginning of the third time window 114 is at most a maximum elapsed time value of 8 hours.
  • the total duration of light treatment is between 3 ⁇ ⁇ and 5 hours including a 30 to 60 minutes "dawn simulation” stage, a second “sleep deprivation stage” of about 3 hours, and a third "bright light stage” of between 30 and 60 minutes.
  • the light provided by the method and/or the apparatus is broad spectrum bright light.
  • this white light may be applied together with colored light, especially colored light having a wavelengh of less than 550 nanometers, and preferably medium wavelength light therapy with light having a wavelength between 520 nm and 535 nm.
  • medium wavelength light is provided, especially during the first 110 and second 112 time windows.
  • short to medium wavelength visible light i.e. blue light of 460 nm, blue-green light of 497 nm, and green light of 525 nm
  • blue light of 460 nm blue-green light of 497 nm
  • green light of 525 nm has been reported in the literature to be more effective for bringing the patient to a state of greater alertness (Wright et al, 2001, Cajochen 2005, Glickman 2005, Benedetti et all 2003).
  • the circadian cycle receives photic input from photoreceptors not used for image-forming which are sensitive to specific wavelengths of light. More particularly, recent research reveals that the mammalian circadian pacemaker, situated in the hypothalamic suprachiasmatic nuclei (SCN), receives environmental photic input (perceived environmental light and dark cycles) from a specialized set of ganglion cells.
  • SCN hypothalamic suprachiasmatic nuclei
  • the photic input entrains endogenous near 24-hour rhythms (including pineal rhythms) to the environmental 24-hour light-dark cycle, to maintain appropriate phase relationships between rhythmic physiological and behavioral processes and periodic environmental factors.
  • light exposure can acutely suppress melatonin secretion.
  • Acute, light-induced melatonin suppression a broadly used indicator for photic input to the SCN, has been used to elucidate the ocular and neural physiology for circadian regulation.
  • medium wavelength light has been found to have a positive mood influencing effect (Benedetti 2003).
  • providing medium wavelength light along with the broad spectrum white light may effective for providing yet another synergistic treatment of mood and psychiatric disorders in the context of sleep deprivation.
  • the light of the first window 110 comprises between at least 5% and at most 30% short to medium wavelength visible light (preferably medium wavelength visible light having a wavelength between 520 and 535 nm).
  • the combination of a gradual dawn process and medium wavelength light may be effective at gently but firmly waking the patient, leaving the patient in an alert state without overly agitating the patient.
  • the proportion of short to medium wavelength exceeds (for example, between 20% colored light and 60% short to medium wavelength light, preferably between 30% and 50% short to medium wavelength light) the proportion during the first window.
  • the.short to medium ⁇ vavelength light is preferably medium wavelength visible light having a wavelength between 520 and 535 nm
  • the presently disclosed therapy which provided extended sleep deprivation of at least 2 ⁇ ⁇ hours, or at least 3 Vz hours, is administered for at least one day.
  • the therapy is administered two or more days, though typically not for more than five consequtive days.
  • the prolonged sleep deprivation light treatment is followed by one or more days of partial sleep deprivation (or advanced sleep deprivation) comprising a dawn simulation stage and a bright light therapy stage. This partial sleep deprivation stage typically provides light that exceeds 500 lux for up to 2 1 A hours, where the bright light treatment lasts at least 30 minutes.
  • a treatment regimen including 1 to 5 days of extended sleep deprivation light therapy followed by partial sleep deprivation light therapy of 10 or more days (for example up to 30 days, for example more than 30 days) may be provided by a control unit operatively linked with a lighting fixture.
  • the present inventor is disclosing for the first time a novel light apparatus for providing the aforementioned light treatments.
  • a block diagram of this novel device is provided in FIG. 2.
  • the light apparatus 200 includes a light source 210 and a controller 212.
  • the controller 212 includes an electronic circuitry (not shown) which can control the intensity of light as a function of time, and optionally the relative intensity of white and colored light as a function of time.
  • the electronic circuitry includes a timer for controlling the duration for which light of any given intensity is emitted, and for controlling when a particular protocol beings.
  • the electronic circuitry of the controller 212 is operative to control is relative intensity of the white and colored lighting elements, and thus, may control the relative proportion of light of various colors.
  • the controller 212 is operatively linked to a user interface (mechanical or electronic) where the user can conveniently select the program (i.e. using a single button, by entering in a number of another sequence of characters for specifying a given protocol, by selecting the protocol from a menu of protocols, etc) for providing the presently disclosed three stage light treatment, thereby obviating the need for the user to program in the desired treatment protocol himself.
  • a user interface mechanical or electronic
  • the user can conveniently select the program (i.e. using a single button, by entering in a number of another sequence of characters for specifying a given protocol, by selecting the protocol from a menu of protocols, etc) for providing the presently disclosed three stage light treatment, thereby obviating the need for the user to program in the desired treatment protocol himself.
  • the light provided by the light source 210 include broad spectrum white light, or is mostly broad spectrum white light.
  • the presently disclosed controller 212 is operative to provide any light treatment method or protocol disclosed herein. It is appreciated that the controller 212 may be provided as any appropriate combination of hardware and/or software elements.
  • light source 210 there is no explicit limitation on the physical form of light source 210, as long as the light apparatus 200 as a whole is configured to provide, as a function of time, light having intensity specified by the parameters of the first, second and third time windows.
  • light apparatus for providing light treatments are well known in the art, and in some embodiments, known light therapy devices may be modified (for example, operatively linked to controller 212) to provide the desired protocols.
  • controller 212 any light source 210 (for example, light apparatus including fluorescent lighting fixtures and light apparatus including a plurality of light emitting diodes (LEDs)) is within the scope of the present invention.
  • the light source 210 includes a light emitting assembly 310 in which a plurality of light emitting diodes (LEDs) 302 are mounted in an LED housing 304.
  • LEDs light emitting diodes
  • arm 306 (drawn not to scale) and is supported by a base (not shown).
  • the user interface i.e. the control panel, not shown
  • the device base may reside in or on the device base (not shown).
  • LED housing 304 has a convex shape in order to focus the light on a specific region (for example, near the eyes of the patient). It is noted that in various embodiments, the light source 212 should include enough
  • LEDs or other lighting elements to provide the requisite level of bright light therapy (for example, at least 2,500 at a given predetermined distance from the LED assembly 310, for example, at least 5,000 at the given predetermined distance from the LED assembly 310, for example, at least 10,000 at the given predetermined distance from the LED assembly 304).
  • the patient may position the light source different distances from her face, and thus, the light treatment apparatus may provided may configured to provide the desired intensities of light at different values of the "predetermined distance.”
  • the predetermined distance is 45 cm, though other IS values, such as 20 cm, 30 cm, 55 cm, 70 cm and 100 cm are all within the scope of the present invention.
  • devices which are configured to operate at a larger distance will include lighting elements (i.e. LEDs or fluorescent lighting elements) configured to emit light of a stronger intensity and/or more lighting elements, in order to provide light of a strong intensity such that the desired intensities are provided at a greater distance.
  • lighting elements i.e. LEDs or fluorescent lighting elements
  • a "light intensity at a predetermined distance” is the intensity measured at a the pre-determined distance (for example, a distance of 18 inches) from a 'central point' of the light source (for example, from a central point 312 of the LED assembly.
  • the device includes a diffuser screen for providing a more uniform emission of light.
  • the diffuser screen includes an UV filter material.
  • the majority of the LEDS are "bright white LEDS" for emitting broad spectrum white light.
  • a certain number of LEDS are colored LEDs, for example, colored LEDs for emitting short to medium wavelength light, or green LEDs for emitting medium wavelength light.
  • the controller 212 is operative to vary the proportion of white and colored light emitted by the device as a function of time.

Abstract

L'invention concerne un dispositif et un procédé destinés à traiter les troubles psychiatriques, les troubles de l'humeur et les troubles des rythmes circadiens au moyen d'un protocole de photothérapie multi-niveau. Le protocole de l'invention porte sur un traitement synergique pouvant inclure jusqu'à quatre thérapies: thérapie par forte lumière, thérapie par privation prolongée de sommeil, thérapie avec simulation de l'aube et photothérapie avec ondes lumineuses courtes à moyennes. Dans certains modes de réalisation, le premier niveau comprend une fenêtre de temps de 20 minutes au cours de laquelle règne la plupart du temps une intensité lumineuse comprise entre 50 et 2000 lux. Sans d'autres modes de réalisation, le second niveau du protocole comprend une seconde fenêtre de temps d'au moins 90 minutes au cours de laquelle l'intensité lumineuse dépasse 100 lux la plupart du temps pendant des périodes de 10 minutes. Selon d'autres modes de réalisation, le troisième niveau du protocole comprend une troisième fenêtre de temps de 60 minutes au cours de laquelle l'intensité lumineuse dépasse 2000 lux le plus souvent. Dans certains modes de réalisation, la lumière est dispensée par une pluralité de D'EL. En général, la lumière comprend une lumière blanche à large spectre avec, dans certains cas, une composant d'onde moyenne comprise par exemple entre 520 et 535 NM.
PCT/IL2006/000212 2005-02-18 2006-02-19 Dispositif et procede de luminotherapie multi-niveau WO2006087723A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US11/884,299 US8852254B2 (en) 2005-02-18 2006-02-19 Apparatus and method for providing a multi-stage light treatment
EP06711194A EP1850912A4 (fr) 2005-02-18 2006-02-19 Dispositif et procede de luminotherapie multi-niveau
IL185243A IL185243A (en) 2005-02-18 2007-08-13 An instrument for determining multi-stage light therapy

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65399805P 2005-02-18 2005-02-18
US60/653,998 2005-02-18

Publications (2)

Publication Number Publication Date
WO2006087723A2 true WO2006087723A2 (fr) 2006-08-24
WO2006087723A3 WO2006087723A3 (fr) 2007-10-25

Family

ID=36916851

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2006/000212 WO2006087723A2 (fr) 2005-02-18 2006-02-19 Dispositif et procede de luminotherapie multi-niveau

Country Status (3)

Country Link
US (1) US8852254B2 (fr)
EP (1) EP1850912A4 (fr)
WO (1) WO2006087723A2 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1808199A2 (fr) 2006-01-11 2007-07-18 Outside In (Cambridge) Limited Source lumineuse pour la photothérapie pour des buts chronobiologiques
WO2013054228A1 (fr) * 2011-10-13 2013-04-18 Koninklijke Philips Electronics N.V. Luminaire a intensite variable presentant un changement de couleur lors de l'obscurcissement
WO2015004440A3 (fr) * 2013-07-08 2015-04-02 Outside In (Cambridge) Ltd Simulateur d'aube
EP2164568B1 (fr) * 2007-05-31 2016-02-24 Koninklijke Philips N.V. Système pour fournir un éclairage et des stimuli physiologiques
US11770888B2 (en) 2021-03-25 2023-09-26 National Yang Ming Chiao Tung University Ambient lighting for improving sleeping disorders, cognition and/or neurological disorders

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0906849B8 (pt) * 2008-01-17 2021-07-27 Koninklijke Philips Nv dispositivo de iluminação, e, método para prover um estímulo para despertar por meio de um dispositivo de iluminação
US8192473B2 (en) * 2008-09-19 2012-06-05 Apira Science, Inc. Phototherapy apparatus for hair, scalp and skin treatment
US9333319B2 (en) * 2009-04-16 2016-05-10 Koninklijke Philips N.V. Illumination device and method for reducing sleep inertia or controlling alertness
EP2422833B1 (fr) * 2009-04-23 2019-01-02 Panasonic Intellectual Property Management Co., Ltd. Système de réveil et procédé pour commander un dispositif d'éclairage utilisé pour celui-ci
CA2805851C (fr) 2009-10-08 2017-03-07 Adam K. Fontecchio Systeme d'eclairage a diodes electroluminescentes
WO2011070794A1 (fr) * 2009-12-11 2011-06-16 有限会社ミニョンベル Dispositif d'induction de sommeil et procédé d'induction de sommeil
EP2697694B1 (fr) * 2011-04-14 2021-06-16 Koninklijke Philips N.V. Appareil de réveil avec fonction répétition
KR102186667B1 (ko) * 2011-05-31 2020-12-08 클라렌슈 피티와이 리미티드 신경학적 병태를 다루는 장치
AU2015261684B2 (en) * 2011-05-31 2017-09-14 Photopharmics, Inc Light-emitting apparatuses for treating and/or diagnosing motor-related neurological conditions
KR20240024299A (ko) * 2011-05-31 2024-02-23 포토파믹스 인코포레이티드 운동 관련 신경 상태들을 치료 및 진단하는 발광 장치들
US20130310903A1 (en) * 2012-03-21 2013-11-21 Catherine Y. LI Anti-Depression Light-Wave Device and Usage Thereof
CN104661706B (zh) * 2012-05-31 2018-11-06 弗托法米克斯股份有限公司 一种用于患有与运动相关的神经疾病的对象的系统
CA2874996C (fr) * 2012-05-31 2023-11-14 Photopharmics, Inc. Appareils pour le traitement et le diagnostic d'affections neurologiques associees aux neurones moteurs
AU2013308871B2 (en) 2012-08-28 2017-04-13 Delos Living Llc Systems, methods and articles for enhancing wellness associated with habitable environments
US10092772B1 (en) 2013-03-15 2018-10-09 Orcus Systems and Solutions, Inc. System and method for treating patients in a controlled setting
US9798458B2 (en) 2013-10-02 2017-10-24 The Joan and Irwin Jacobs Technion-Cornell Innovation Institute Methods, systems, and apparatuses for accurate measurement and real-time feedback of solar ultraviolet exposure
US9880052B2 (en) 2013-10-02 2018-01-30 The Joan and Irwin Jacobs Technion-Cornell Innovation Institute Methods, systems, and apparatuses for accurate measurement and real-time feedback of solar ultraviolet exposure
WO2015051013A1 (fr) * 2013-10-02 2015-04-09 The Joan & Irwin Jacobs Technion-Cornell Innovation Institute (Jacobs Institute) Système portable et procédé pour mesurer et surveiller des rayonnements de lumières ultraviolette, visible, et infrarouge afin de fournir des recommandations médicales personnalisées, d'empêcher les maladies, et d'améliorer la gestion thérapeutique
US20150234207A1 (en) * 2014-02-17 2015-08-20 Daniel Koifman Device and method for selective wavelength filtration and selective wavelength transmission for therapeutic effect
WO2015130786A1 (fr) 2014-02-28 2015-09-03 Delos Living Llc Systèmes, procédés et articles pour améliorer le bien-être associé à des environnements habitables
US10100987B1 (en) 2014-09-24 2018-10-16 Ario, Inc. Lamp with directional, independently variable light sources
AU2016202287B2 (en) 2015-01-13 2021-04-01 Delos Living Llc Systems, methods and articles for monitoring and enhancing human wellness
US20160235940A1 (en) * 2015-02-17 2016-08-18 Daniel Andrew Koifman Device and method for selective wavelength filtration and selective wavelength transmission for therapeutic effect
US10527490B2 (en) 2015-08-25 2020-01-07 The Joan and Irwin Jacobs Technion-Cornell Innovation Institute Methods, systems, and apparatuses for accurate measurement and real-time feedback of solar ultraviolet exposure
US10739253B2 (en) 2016-06-07 2020-08-11 Youv Labs, Inc. Methods, systems, and devices for calibrating light sensing devices
JP6735471B2 (ja) * 2016-06-24 2020-08-05 パナソニックＩｐマネジメント株式会社 発光装置、浴光方法及び発光システム
WO2018039433A1 (fr) 2016-08-24 2018-03-01 Delos Living Llc Systèmes, procédés et articles permettant d'accroître le bien-être associé à des environnements habitables
USD829112S1 (en) 2016-08-25 2018-09-25 The Joan and Irwin Jacobs Technion-Cornell Innovation Institute Sensing device
US10502374B2 (en) 2017-01-30 2019-12-10 Ideal Industries Lighting Llc Light fixtures and methods
US11668481B2 (en) 2017-08-30 2023-06-06 Delos Living Llc Systems, methods and articles for assessing and/or improving health and well-being
US11649977B2 (en) 2018-09-14 2023-05-16 Delos Living Llc Systems and methods for air remediation
US11285335B2 (en) 2018-10-08 2022-03-29 Biohacked, Inc. Photo-therapeutic method and apparatus
US10876886B2 (en) 2018-10-19 2020-12-29 Youv Labs, Inc. Methods, systems, and apparatuses for accurate measurement of health relevant UV exposure from sunlight
US11844163B2 (en) 2019-02-26 2023-12-12 Delos Living Llc Method and apparatus for lighting in an office environment
WO2020198183A1 (fr) 2019-03-25 2020-10-01 Delos Living Llc Systèmes et procédés de surveillance acoustique
US20220296917A1 (en) * 2021-03-19 2022-09-22 Rebalance Tech Corp. Light therapy device for non-invasive stimulation of the human brain
US11944840B2 (en) 2021-04-08 2024-04-02 Niraxx Light Therapeutics, Inc. Photobiomodulation therapy garment, methods and uses
JP2024514558A (ja) 2021-04-08 2024-04-02 ニーラックス インコーポレイテッド フォトバイオモジュレーション療法用衣類、方法、及びその使用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5545192A (en) * 1987-06-26 1996-08-13 Brigham And Women's Hospital Intermittent use of bright light to modify the circadian phase
US4930504A (en) 1987-11-13 1990-06-05 Diamantopoulos Costas A Device for biostimulation of tissue and method for treatment of tissue
US4858609A (en) * 1987-12-04 1989-08-22 Cole Roger J Bright light mask
JPH09213101A (ja) * 1995-11-27 1997-08-15 Matsushita Electric Works Ltd 携帯用光照射装置
US7038398B1 (en) * 1997-08-26 2006-05-02 Color Kinetics, Incorporated Kinetic illumination system and methods
US6459919B1 (en) * 1997-08-26 2002-10-01 Color Kinetics, Incorporated Precision illumination methods and systems
DE19924676A1 (de) 1999-05-29 2000-11-30 Dietmar Wolter Hüftgelenkprothese
CA2317319A1 (fr) 2000-03-14 2001-09-14 The Litebook Company Ltd Dispositif de phototherapie
PT1422975E (pt) * 2000-04-24 2010-07-09 Philips Solid State Lighting Produto ‚ base de leds
US20030233138A1 (en) * 2002-06-12 2003-12-18 Altus Medical, Inc. Concentration of divergent light from light emitting diodes into therapeutic light energy
US20080091250A1 (en) * 2002-09-26 2008-04-17 Lumiport, Llc Light therapy desk lamp
US20050015122A1 (en) * 2003-06-03 2005-01-20 Mott Christopher Grey System and method for control of a subject's circadian cycle
US10252079B2 (en) * 2003-06-06 2019-04-09 Koninklijke Philips N.V. Hand-held light therapy apparatus
CA2532657A1 (fr) 2003-07-14 2005-01-20 Charles A. Czeisler Procede pour modifier ou retablir le cycle circadien en utilisant un rayonnement lumineux de faible longueur d'onde

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of EP1850912A4 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1808199A2 (fr) 2006-01-11 2007-07-18 Outside In (Cambridge) Limited Source lumineuse pour la photothérapie pour des buts chronobiologiques
EP1808199A3 (fr) * 2006-01-11 2008-04-09 Outside In (Cambridge) Limited Source lumineuse pour la photothérapie pour des buts chronobiologiques
US9433799B2 (en) 2006-01-11 2016-09-06 Outside In (Cambridge) Ltd. Phototherapy lights
EP2164568B1 (fr) * 2007-05-31 2016-02-24 Koninklijke Philips N.V. Système pour fournir un éclairage et des stimuli physiologiques
WO2013054228A1 (fr) * 2011-10-13 2013-04-18 Koninklijke Philips Electronics N.V. Luminaire a intensite variable presentant un changement de couleur lors de l'obscurcissement
US9107251B2 (en) 2011-10-13 2015-08-11 Koninklijke Philips N.V. Dimmable luminary featuring colour change during dimming
RU2608175C2 (ru) * 2011-10-13 2017-01-17 Конинклейке Филипс Н.В. Источник света с изменением яркости, отличающийся изменением цвета при изменении яркости
WO2015004440A3 (fr) * 2013-07-08 2015-04-02 Outside In (Cambridge) Ltd Simulateur d'aube
US11770888B2 (en) 2021-03-25 2023-09-26 National Yang Ming Chiao Tung University Ambient lighting for improving sleeping disorders, cognition and/or neurological disorders

Also Published As

Publication number Publication date
EP1850912A4 (fr) 2009-07-01
EP1850912A2 (fr) 2007-11-07
US8852254B2 (en) 2014-10-07
US20080103561A1 (en) 2008-05-01
WO2006087723A3 (fr) 2007-10-25

Similar Documents

Publication Publication Date Title
US8852254B2 (en) Apparatus and method for providing a multi-stage light treatment
Terman et al. Light therapy for seasonal and nonseasonal depression: efficacy, protocol, safety, and side effects
Blume et al. Effects of light on human circadian rhythms, sleep and mood
Avery et al. Dawn simulation and bright light in the treatment of SAD: a controlled study
US8303635B2 (en) Suprachiasmatic nucleus inducing, melatonin suppressing light emitting device to enhance wake cycle
US8894696B2 (en) Suprachiasmatic nucleus inducing, melatonin suppressing light emitting device to enhance wake cycle
US6623512B1 (en) Circadian rhythm reset method and device
Terman et al. Circadian rhythm phase advance with dawn simulation treatment for winter depression
Park et al. Effects of color temperature and brightness on electroencephalogram alpha activity in a polychromatic light-emitting diode
US20150234207A1 (en) Device and method for selective wavelength filtration and selective wavelength transmission for therapeutic effect
Schmidt et al. Light exposure via a head‐mounted device suppresses melatonin and improves vigilant attention without affecting cortisol and comfort
Sloane et al. Light as therapy for sleep disorders and depression in older adults
Partonen Effects of morning light treatment on subjective sleepiness and mood in winter depression
Kolanowski The clinical importance of environmental lighting to the elderly
Gooley Light-induced resetting of circadian rhythms in humans
JP2015502813A (ja) 照明信号、システム、および方法
REA et al. What is" healthy lighting?"
Figueiro et al. Spectral sensitivity of the circadian system
Byrne et al. Seasonal affective disorder and light therapy
Boyce Lemmings, light, and health
US20160235940A1 (en) Device and method for selective wavelength filtration and selective wavelength transmission for therapeutic effect
EP2905544A1 (fr) Hotte de cuisine pour la photothérapie comprenant une source lumineuse à éclairage élevé
RU2319521C2 (ru) Способ светового воздействия на физическое и психоэмоциональное состояние человека
WO2023153478A1 (fr) Procédé d'amélioration de conditions physiologiques par photostimulation et dispositif à utiliser associés
US20240009420A1 (en) Systems and methods for improving sleep and other indications, including treating anxiety

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 185243

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 11884299

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006711194

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2006711194

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 11884299

Country of ref document: US